2002-09-07-Bain-Electric_channels_can_ease_drug_firms_squeeze_1页_63kb

Summary of Biotechnology and Pharmaceutical Productivity

The pharmaceutical industry faces a productivity squeeze, with tight demands from investors, regulators, and consumers for growth, lower prices, and efficiency. To address this, many companies are leveraging electronic technologies to streamline operations, reduce development costs, and shorten timelines for drug discovery and market entry.

Key Innovations

• E-Research: Utilization of high-throughput technologies and Internet-based systems to analyze data more efficiently, improving collaboration among researchers and partners.
• E-Detailing: Allows physicians to access drug information via web or phone, saving companies $100–$125 per session and cutting development costs by 10–15%.
• E-Clinical Trials: Adoption of Web-based and automated tools reduces average trial times by 30%, lowers recruitment and tracking costs, and enhances data management; only about 10% of trials currently use these methods.
• E-Marketing: Shifts sales focus from costly commission-driven reps to digital channels, helping companies reach consumers directly and reinforce brand loyalty, potentially saving millions in sales efforts.

Strategic Impact

• Companies are closing a gap between projected and needed drug outputs (1.8/year expected vs. 3–4/year required), necessitating at least a 30% timeline reduction in drug development.
• Despite advancements, e-technologies are not yet broadly implemented across all firms, but early adopters like Aventis, Pfizer, and Novartis are gaining competitive advantages.
• These strategies offer alternatives to mergers for boosting productivity, enabling pharma firms to compete on agility and value rather than brute force.